Enliven Net Income from 2010 to 2024
| ELVN Stock | 25.41 1.06 4.35% |
Net Loss | First Reported 2019-03-31 | Previous Quarter -19.9 M | Current Value -23.2 M | Quarterly Volatility 10.8 M |
Check Enliven Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enliven Therapeutics' main balance sheet or income statement drivers, such as Other Operating Expenses of 87.7 M, Research Development of 67.8 M or Total Operating Expenses of 87.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.1. Enliven financial statements analysis is a perfect complement when working with Enliven Therapeutics Valuation or Volatility modules.
Enliven | Net Income |
Latest Enliven Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Enliven Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Enliven Therapeutics financial statement analysis. It represents the amount of money remaining after all of Enliven Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Enliven Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enliven Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (71.58 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Enliven Net Income Regression Statistics
| Arithmetic Mean | (23,099,187) | |
| Coefficient Of Variation | (88.47) | |
| Mean Deviation | 14,669,849 | |
| Median | (11,337,000) | |
| Standard Deviation | 20,436,613 | |
| Sample Variance | 417.7T | |
| Range | 60.2M | |
| R-Value | (0.77) | |
| Mean Square Error | 180.1T | |
| R-Squared | 0.60 | |
| Significance | 0.0007 | |
| Slope | (3,538,541) | |
| Total Sum of Squares | 5847.2T |
Enliven Net Income History
Other Fundumenentals of Enliven Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Enliven Therapeutics Net Income component correlations
About Enliven Therapeutics Financial Statements
Enliven Therapeutics investors utilize fundamental indicators, such as Net Income, to predict how Enliven Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -71.6 M | -68 M | |
| Net Loss | -71.6 M | -68 M | |
| Net Loss | -22.3 M | -23.4 M | |
| Net Loss | (2.01) | (2.11) | |
| Net Income Per E B T | 0.90 | 0.80 |
Pair Trading with Enliven Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enliven Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enliven Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Enliven Stock
| 0.84 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.72 | RGNX | Regenxbio | PairCorr |
| 0.68 | INKT | Mink Therapeutics | PairCorr |
| 0.63 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
| 0.61 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
The ability to find closely correlated positions to Enliven Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enliven Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enliven Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enliven Therapeutics to buy it.
The correlation of Enliven Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enliven Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enliven Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enliven Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Enliven Therapeutics Correlation against competitors. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.89) | Return On Assets (0.21) | Return On Equity (0.31) |
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.